What is the global prevalence of mycobacterium chelonae infection?

Updated: Dec 20, 2018
  • Author: Alfred Scott Lea, MD; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print

The global epidemiology of pulmonary NTM infections has been reviewed, with limited reported information about M chelonae. [34] The incidence and prevalence of NTM varies considerably, and M chelonae has been reported in South America, Australia, Taiwan, China, Japan, Canada, Korea, Germany, Italy, France, Switzerland, the United Kingdom, and The Netherlands. [1]

A 2-year review of NTM isolates in a South Korean medical center was evaluated for clinical relevance. Approximately one fourth of 1548 isolates from 794 patients were found to be clinical significant, with M chelonae representing 29 isolates from 25 patients. Of those, only 6 patients (3%) were determined to be definite or probable NTM infection based on American Thoracic Society (ATS) and British Thoracic Society (BTS) guidelines. [35]

A national Australian survey in 2000 reported that all 22 M chelonae pulmonary isolates were not considered pathogens, while the organism was considered pathogenic in 17 of 131 soft-tissue isolates. [36]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!